HBV/HDV Multiplex PCR Test at Dr. Essa Lab, Karachi, PK

HBV/HDV Multiplex PCR at Dr. Essa Lab

The HBV/HDV Multiplex PCR test is an advanced molecular diagnostic assay designed for the simultaneous detection and quantification of Hepatitis B Virus (HBV) DNA and Hepatitis D Virus (HDV) RNA in human plasma or serum. Developed to address the clinical challenges of viral hepatitis co-infections, this multiplex real-time polymerase chain reaction (PCR) assay provides a highly sensitive, specific, and rapid method for evaluating patients at risk of progressive liver disease. Hepatitis B is caused by a double-stranded DNA virus of the Hepadnaviridae family, while Hepatitis D is caused by a defective single-stranded RNA virus (deltavirus) that requires the presence of the Hepatitis B surface antigen (HBsAg) to assemble its outer envelope, replicate, and infect hepatocytes. Consequently, HDV infection occurs only in individuals who are already infected with HBV, either as a simultaneous co-infection or as a superinfection on a pre-existing chronic HBV carrier state.

Dr. Essa Laboratory & Diagnostic Centre, a premier diagnostic institution in Karachi, Pakistan, utilizes state-of-the-art molecular biology platforms to perform this multiplex PCR assay. By amplifying highly conserved regions of both the HBV DNA and HDV RNA genomes in a single reaction tube, the laboratory delivers highly precise quantitative viral load measurements. This multiplex approach minimizes sample volume requirements, reduces the risk of laboratory cross-contamination, and significantly shortens turnaround times compared to running separate single-target assays. Clinically, identifying the presence and active replication of both viruses is of paramount importance. HDV superinfection in chronic HBV patients is associated with the most severe form of chronic viral hepatitis, leading to rapid progression to liver cirrhosis, portal hypertension, liver failure, and an increased risk of hepatocellular carcinoma (HCC). This test serves as an indispensable tool for hepatologists, gastroenterologists, and infectious disease specialists in establishing baseline viral activity, planning targeted therapeutic interventions, and monitoring patient response to antiviral regimens.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure specimen integrity and the accuracy of molecular diagnostic results. While molecular PCR assays are not directly affected by dietary intake, the following preparation guidelines are recommended for patients undergoing the HBV/HDV Multiplex PCR test at Dr. Essa Lab:

• Fasting Recommendations: Although strict fasting is not mandatory for nucleic acid amplification tests, a mild fast of 4 to 6 hours prior to venipuncture is highly recommended. This helps prevent lipemia (excess lipids in the blood), which can sometimes interfere with automated pipetting systems and optical detection during the real-time PCR process.
• Medication Disclosure: Patients must inform their healthcare provider and the laboratory staff of all current medications, particularly antiviral therapies such as Tenofovir, Entecavir, or Pegylated Interferon. These medications directly suppress viral replication and will significantly influence the quantitative results of the PCR assay.
• Hydration: Adequate hydration is encouraged before the blood draw, as it facilitates easier venous access and ensures a smooth venipuncture experience.
• Prior Test Results: It is highly beneficial to bring previous laboratory reports, especially HBsAg status, liver function tests (LFTs), and prior viral load measurements, to assist in clinical correlation.

During the Procedure

The collection and processing of specimens for molecular diagnostics follow strict protocols to prevent contamination and preserve viral nucleic acids. The procedure at Dr. Essa Lab involves the following clinical steps:

• Venipuncture: A certified phlebotomist will identify a suitable vein, typically in the antecubital fossa of the arm. The site is thoroughly cleansed with an antiseptic solution (70% isopropyl alcohol) to eliminate skin flora and prevent contamination.
• Sample Collection: Approximately 3 to 5 mL of venous blood is collected into a sterile tube containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant (lavender-top tube). EDTA is the preferred anticoagulant for molecular testing as it preserves viral particles and prevents the degradation of viral DNA and RNA.
• Specimen Processing: Immediately after collection, the tube is gently inverted several times to mix the blood with the anticoagulant. The specimen is then transported to the molecular diagnostics department under controlled temperature conditions. The blood is centrifuged to separate the plasma from cellular components. The plasma is then aliquoted into sterile, nuclease-free tubes.
• Nucleic Acid Extraction: Using automated extraction platforms, viral DNA (HBV) and viral RNA (HDV) are simultaneously isolated from the plasma sample. Automated extraction ensures high purity and yield of nucleic acids while eliminating potential PCR inhibitors.
• Amplification and Detection: The extracted nucleic acids undergo reverse transcription (to convert HDV RNA into complementary DNA) followed by multiplex real-time PCR amplification. Specific primers and fluorescent-labeled probes target the conserved regions of the HBV and HDV genomes. The real-time PCR instrument detects and measures the fluorescent signals emitted during each cycle, allowing for precise quantification of the viral loads against standard curves calibrated to World Health Organization (WHO) international standards.
• Duration and Experience: The venipuncture itself takes less than five minutes and involves minimal discomfort, comparable to a brief pinch. The entire laboratory analytical process is completed within a controlled environment, requiring no further active participation from the patient.

When is a HBV/HDV Multiplex PCR Performed?

Chronic Hepatitis B Monitoring

Physicians request this multiplex PCR test for patients diagnosed with chronic Hepatitis B, particularly those residing in or originating from regions with a high prevalence of HDV, such as parts of Pakistan. Regular monitoring of HBV DNA levels is critical to assess the phase of chronic infection (e.g., immune-active, inactive carrier, or HBeAg-negative chronic hepatitis) and to determine the necessity of initiating antiviral therapy. Simultaneously checking for HDV RNA ensures that underlying, clinically silent HDV co-infections are not overlooked, which is vital because HDV can suppress HBV replication, leading to falsely reassuring low HBV DNA levels while liver damage continues to progress.

Unexplained Acute Exacerbation of Hepatitis B

When a patient with stable, well-controlled chronic Hepatitis B experiences a sudden, unexplained flare-up of liver enzymes (such as alanine aminotransferase, ALT, and aspartate aminotransferase, AST) or presents with acute-on-chronic liver failure, a superinfection with HDV must be suspected. The multiplex PCR test is performed immediately to differentiate between a spontaneous HBV reactivation flare and an acute HDV superinfection. Rapid identification of HDV RNA in this clinical scenario is crucial, as HDV superinfection carries a high risk of fulminant hepatic failure and requires immediate, specialized clinical management.

Assessment of High-Risk Patient Populations

Screening and diagnostic testing using the HBV/HDV Multiplex PCR are highly indicated for individuals within high-risk categories who present with positive HBsAg. These populations include patients undergoing chronic hemodialysis, individuals with a history of injection drug use, patients receiving frequent blood transfusions, and those with multiple sexual partners. Because HDV is transmitted through parenteral routes similar to HBV, these cohorts have a significantly higher incidence of co-infection. Early detection through molecular testing allows for timely intervention before irreversible liver damage occurs.

Pre-Therapy Evaluation and Treatment Planning

Before initiating any antiviral regimen for chronic viral hepatitis, establishing baseline quantitative levels of both HBV DNA and HDV RNA is a clinical necessity. The therapeutic approach for mono-infected HBV patients (typically nucleos/tide analogues like Tenofovir or Entecavir) differs substantially from the treatment of HDV-infected patients (which historically relies on Pegylated Interferon-alpha or newer entry inhibitors like Bulevirtide). Knowing the precise viral load of both pathogens allows clinicians to select the correct therapeutic agents, determine appropriate dosages, and establish a baseline against which treatment efficacy can be measured.

Monitoring Response to Antiviral Therapy

During the course of antiviral treatment, serial testing with the HBV/HDV Multiplex PCR is performed at scheduled intervals (e.g., every 12 to 24 weeks) to evaluate therapeutic efficacy. A successful response is characterized by a progressive decline in viral loads, ideally leading to undetectable levels of both HBV DNA and HDV RNA. Conversely, persistent viremia or a sudden rise in viral loads (virological breakthrough) can indicate poor patient compliance, the development of drug-resistant viral mutations, or the need to adjust the therapeutic regimen.

What Does a HBV/HDV Multiplex PCR Detect?

The HBV/HDV Multiplex PCR assay is capable of detecting and quantifying a wide range of clinical findings, which directly influence patient management. The primary findings and clinical interpretations include:

• Undetectable HBV DNA and Undetectable HDV RNA: Indicates the absence of active replication for both viruses. This is the ideal therapeutic goal and can represent a successful response to treatment or an inactive carrier state.
• Detectable HBV DNA and Undetectable HDV RNA: Confirms active Hepatitis B viral replication without active Hepatitis D co-infection. This points to HBV mono-infection.
• Undetectable HBV DNA and Detectable HDV RNA: Indicates active Hepatitis D replication with suppressed Hepatitis B replication. This is a classic finding in HDV superinfection, where the HDV virus actively suppresses the replication of the helper HBV virus.
• Detectable HBV DNA and Detectable HDV RNA: Confirms active replication of both Hepatitis B and Hepatitis D viruses, indicating an active co-infection or superinfection.
• Quantitative HBV Viral Load (expressed in IU/mL): Measures the exact concentration of HBV DNA in the blood, reflecting the level of viral replication in the hepatocytes.
• Quantitative HDV Viral Load (expressed in copies/mL or IU/mL): Measures the exact concentration of HDV RNA, providing a baseline for monitoring the severity of HDV infection and response to therapy.
• Low-Level HBV Viremia: Detection of HBV DNA below the clinical threshold for treatment but above the limit of detection, requiring close monitoring.
• High-Level HBV Viremia: High viral loads (typically >20,000 IU/mL in HBeAg-positive patients) indicating high infectivity and active hepatic inflammation.
• Low-Level HDV Viremia: Early-stage HDV infection or partial suppression under antiviral therapy.
• High-Level HDV Viremia: Active, aggressive HDV replication associated with a high risk of rapid progression to liver cirrhosis.
• Virological Response: A significant decrease (usually defined as a >2 log10 reduction) in viral loads compared to baseline measurements.
• Complete Virological Clearance: Both viral targets falling below the lower limit of analytical detection of the assay.
• Virological Breakthrough: A sudden increase in viral load (usually >1 log10 increase) in a patient who previously achieved viral suppression, suggesting resistance or non-adherence.
• Occult Hepatitis B Infection: Detection of very low levels of HBV DNA in patients who test negative for HBsAg but may have anti-HBc antibodies.
• HDV Genotype Implications: While not a direct genotyping test, high viral loads across multiplex targets prompt consideration of regional genotype severity (e.g., HDV Genotype 1 is common and associated with severe disease).
• Resolution of HDV Infection: Disappearance of HDV RNA from the blood, indicating clearance of the virus, which is rare in chronic cases but possible after successful interferon therapy.
• Persistent HDV Replication: Ongoing detection of HDV RNA over a period of six months or more, confirming chronic HDV infection.
• Suppression of HBV by HDV: A clinical finding where HDV replication is dominant, and HBV DNA is kept at low or undetectable levels.
• Reactivation of HBV: A sudden rise in HBV DNA levels, often observed if HDV replication is suppressed or during immunosuppressive therapy.
• Indication for Non-Invasive Fibrosis Assessment: High viral loads of both pathogens indicate a high risk of hepatic fibrosis, prompting the need for a Fibroscan or liver biopsy.
• Evaluation of Transmission Risk: High quantitative viral loads correlate with increased infectivity through blood-borne or sexual exposure.
• Pre-Transplant Evaluation Finding: Quantification of viral loads in patients with end-stage liver disease undergoing evaluation for liver transplantation to plan post-transplant prophylaxis.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Laboratory & Diagnostic Centre is committed to providing accurate and timely diagnostic reports. Due to the complex molecular nature of the HBV/HDV Multiplex PCR test, which involves nucleic acid extraction, reverse transcription, and real-time amplification, the turnaround time is typically within 3 to 5 working days. This timeframe ensures that rigorous quality control checks, including the verification of internal controls and calibration standards, are fully completed before results are released.

Patients and referring physicians can access reports through multiple convenient channels. Once the report is finalized, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed directly from the official Dr. Essa Lab website portal using the unique patient ID and lab number provided on the receipt. Additionally, physical copies of the reports can be collected from any of the numerous Dr. Essa Lab collection centers located across Karachi and other major cities. The reports are presented in a clear, comprehensive format, detailing the quantitative values for both HBV DNA and HDV RNA, along with the analytical sensitivity and linear range of the assay for easy clinical interpretation.

HBV/HDV Multiplex PCR Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HBV DNA (Quantitative)	Undetectable (Target Not Detected)	Detectable viral load (expressed in IU/mL), indicating active HBV replication and potential infectivity.
HDV RNA (Quantitative)	Undetectable (Target Not Detected)	Detectable viral load (expressed in copies/mL or IU/mL), confirming active HDV replication.
Co-infection Status	Negative for both viral genomes	Simultaneous detection of both HBV DNA and HDV RNA, indicating active double infection.
Superinfection Status	Negative for HDV RNA	Presence of HDV RNA in a patient with pre-existing chronic HBV, often accompanied by low or suppressed HBV DNA.
Viral Suppression	Complete suppression (Undetectable)	Persistent high viral loads of either or both viruses despite ongoing antiviral therapy, indicating potential drug resistance.
Liver Enzyme Correlation (ALT/AST)	Normal reference ranges (typically <35-50 U/L)	Markedly elevated transaminases, reflecting active hepatic necroinflammation driven by viral replication.
Total Bilirubin Correlation	Normal reference range (0.2 – 1.2 mg/dL)	Elevated bilirubin levels (jaundice), indicating acute liver injury or advanced, decompensated liver disease.
Serum Albumin / Prothrombin Time (PT)	Normal synthetic function (Albumin: 3.5-5.0 g/dL; PT: 11-13.5 seconds)	Decreased albumin and prolonged PT, indicating impaired hepatic synthetic capacity due to severe chronic co-infection.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for HBV/HDV Multiplex PCR?

• Experienced Healthcare Professionals: Dr. Essa Lab is staffed by highly qualified pathologists, molecular biologists, and laboratory technologists specializing in advanced viral diagnostics.
• Patient-Focused Care: The laboratory prioritizes patient comfort, offering professional counseling, gentle phlebotomy services, and clear guidance throughout the testing process.
• Quality Diagnostic Services: Utilizing state-of-the-art automated molecular platforms, Dr. Essa Lab ensures high precision, sensitivity, and reproducibility for all PCR assays.
• Professional Reporting: Reports are structured to be comprehensive yet easy to understand, providing quantitative values aligned with international standards (WHO).
• Modern Diagnostic Approach: The molecular department employs multiplex real-time PCR technology, allowing for the simultaneous detection of multiple pathogens from a single sample.
• Comfortable Environment: All collection centers and main laboratory branches are designed to provide a clean, safe, and welcoming environment for patients.
• Convenient Location: With an extensive network of collection points across Karachi and other regions, patients can easily access testing services close to home.
• Commitment to Accurate Diagnosis: Dr. Essa Lab adheres to strict internal and external quality assurance protocols, ensuring that every result is highly reliable and clinically actionable.